Here’s my recent analysis published for BullBear Traders members:
Thusfar markets have proceeded pretty much as my analysis had anticipated. US equities are now fairly well confirmed to be in a major Wave 3 advance. Increasingly, signals are indicating that the 10 year long lateral bear market is…
THE EWI ARGUMENT:
A Critical Analysis of Robert Prechter and Elliott Wave International
In this article I analyze the recent work of Robert Prechter’s “Elliott Wave International”, evaluating…
Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma and mantle cell lymphoma. It is also developing an automated cell culture instrument. The company also sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies.
Next coming catalyst event for INVO Bioscience might come from Asia, with the expected Class II medical device classification for the INVOcell in China.
In August 10th, INVO Bioscience along with his distribution partner The Progressive Group, one of the larger med device and equipment distributors in this area, have started the registration process with Chinese FDA authorities.
“During the third quarter of 2010, our focus was on preparation of the 5 modules that make up the NDA submission for Marqibo(R)” stated Steven R. Deitcher, M.D., President and Chief Executive Officer of Hana Biosciences. “An analysis of data from the Menadione Topical Lotion Phase 1 program showed that it was generally safe and well tolerated. In addition, the dose limiting toxicity and apparent maximum tolerated lotion strength were identified. Our strategy is to seek a partner to enhance and accelerate the continued development of Menadione Topical Lotion.
I’ll try my hand at some live blogging here as I sit in on a seminar with Yu-Dee Chang sponsored by Essex Futures in Orange County, CA. I’ll be typing and updating as the session proceeds.
Mr. Chang is expected to run the gamut in a fundamental review of markets. Economy, Dollar, Treasuries, Interest Rates, Stocks, Metals, Commodities.
A little humor with a less
Intermediate Term Decline Underway
11/10/10 BullBear Market Report
(Originally published on 11/10/10 for BullBear Trading
members and updated on 11/12/10).
I’ve been seeing technical divergences for weeks now and so far no real pullback has resulted. The major indices have now taken out the April highs and have been trading at those levels for about a week now. As a result there a
(Excerpted from the most recent BullBear Weekend Report)
In last week’s BullBear Weekend Report I called for some profit taking and indicated that the market was likely set up for a pullback. This week the market continued to trade in a sideways pattern while the technical conditions suggestive of a correction deepened. As we go into the mid-term election and the November FOMC meeting, my long term sta